GLP-1 Agonists for Weight Loss

FDA-Approved GLP-1 Agonists for Weight Loss

• The FDA recommends liraglutide (3.0 mg daily) and semaglutide (2.4 mg weekly) for weight loss in individuals with BMI ≥30 or BMI ≥27 with weight-related comorbidities, such as hypertension, type 2 diabetes, or obstructive sleep apnea 1, 2, 3
• The American College of Cardiology-aligned FDA approval indicates liraglutide (3.0 mg daily) was approved in 2014 for weight management in adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity 2, 4
• Semaglutide (2.4 mg weekly) was approved by the FDA in 2021 for weight management with the same BMI criteria as liraglutide, as recommended by the American Heart Association 1, 2, 4
• Tirzepatide (a dual GIP/GLP-1 receptor agonist) was approved by the FDA in November 2023 for weight management, according to the American Diabetes Association 4

Efficacy Comparison

• Semaglutide 2.4 mg weekly demonstrates superior weight loss compared to liraglutide, with a mean weight loss of 14.9% from baseline in non-diabetic patients with obesity in the STEP trial, as reported by the National Institutes of Health 1, 4
• The Endocrine Society notes that semaglutide produces greater weight loss (6.1-17.4%) compared to patients with diabetes (4-6.2%) 1
• Tirzepatide shows even greater efficacy with weight loss of 15-20.9% at higher doses (15 mg weekly), according to the American Association of Clinical Endocrinologists 1, 4

Mechanism of Action for Weight Loss

• The American College of Cardiology states that GLP-1 receptor agonists promote weight loss through multiple mechanisms, including activation of GLP-1 receptors in the hypothalamus and brainstem to suppress appetite and increase satiety 1, 2
• The European Association for the Study of Obesity reports that delayed gastric emptying leads to prolonged feelings of fullness, and reduction in caloric intake through central nervous system effects 1, 2, 5

Important Clinical Considerations

• The American Heart Association recommends that weight regain occurs after discontinuation of therapy, suggesting long-term use is necessary for sustained weight loss 4
• Common adverse effects include gastrointestinal symptoms (nausea, vomiting, diarrhea, dyspepsia), as noted by the National Institute of Diabetes and Digestive and Kidney Diseases 1
• The American College of Cardiology suggests that dosing recommendations should start at low doses and titrate upward slowly to minimize gastrointestinal side effects 1
• The Endocrine Society recommends that for weight loss, higher doses are typically required compared to diabetes management (liraglutide 3.0 mg vs 1.8 mg; semaglutide 2.4 mg vs 1.0 mg) 4

Additional Benefits Beyond Weight Loss

• The American College of Cardiology reports that GLP-1 receptor agonists reduce risk of cardiovascular events in high-risk patients 1, 4
• The American Diabetes Association notes that improvements in metabolic parameters include reduction in HbA1c, improved lipid profiles 1
• The American Association for the Study of Liver Diseases suggests that potential benefits for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) exist 6, 7

GLP-1 Receptor Agonist Resistance: Mechanisms and Management

Mechanisms of GLP-1 Resistance

• Tachyphylaxis can develop with long-acting GLP-1 receptor agonists, reducing their effect on gastric emptying and satiety signals in patients, according to the Anaesthesia journal 8
• Continuous exposure to GLP-1 receptor agonists can lead to adaptation, with diminished effects on gastric emptying compared to acute or intermittent administration, as shown in studies using scintigraphy 8
• Patients with diabetes typically experience less weight loss (4-6.2%) compared to non-diabetic patients (6.1-17.4%) when using GLP-1 receptor agonists, suggesting metabolic factors influence response 8

Clinical Factors Contributing to Resistance

• Poor adherence due to gastrointestinal side effects (nausea, vomiting, diarrhea) can contribute to GLP-1 receptor agonist resistance in patients, as reported in Diabetes Care 9
• Underlying metabolic conditions can affect energy expenditure or hunger-satiety mechanisms, influencing GLP-1 receptor agonist response in patients 9

Management Strategies for GLP-1 Resistance

• Reducing meal size and limiting alcohol and carbonated drinks can help manage gastrointestinal symptoms associated with GLP-1 receptor agonist use, as suggested in Anaesthesia 8
• For patients with BMI >35 kg/m², GLP-1 receptor agonists may provide insufficient weight loss alone, and bariatric surgery may eventually be needed for sustainable results, according to Diabetes Care 9

Special Considerations

• GLP-1 receptor agonists may not be preferred in older adults experiencing unexplained weight loss, and gastrointestinal side effects may be more problematic in this population, as noted in Diabetes Care 10
• Continuing GLP-1 receptor agonists throughout the perioperative period is recommended, but awareness of delayed gastric emptying effects is necessary, as reported in Anaesthesia 11
• The risk of pulmonary aspiration during general anesthesia due to delayed gastric emptying should be considered when using GLP-1 receptor agonists, as mentioned in Anaesthesia 11

Expected Weight Loss with GLP-1 Agonists Over Six Months

Weight Loss Expectations by Specific GLP-1 Agonist

• Patients on semaglutide can expect approximately 10-12% weight loss over six months, according to the American College of Cardiology guidelines 12, 13
• Semaglutide provides the most significant weight reduction among GLP-1 agonists, with approximately 10-12% total body weight loss at 6 months 12, 13
• Clinical trials show weight loss with semaglutide continues beyond 6 months, reaching 14.9% at 68 weeks in non-diabetic patients with obesity 14
• Liraglutide produces approximately 4-6% weight loss at 6 months, as recommended by the American Heart Association 12, 15
• If a patient has not lost at least 4% of body weight after 16 weeks of treatment with liraglutide, the medication should be discontinued, according to the American College of Cardiology guidelines 12, 13
• Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces approximately 8-12% weight loss at 6 months and 15-21% weight loss at 72 weeks, making it the most effective GLP-1-based therapy currently available 14

Factors Affecting Weight Loss Response

• Gastrointestinal side effects such as nausea, vomiting, and diarrhea are common with GLP-1 agonists and may lead to treatment discontinuation, affecting overall weight loss outcomes, as reported by the American Gastroenterological Association 12, 13

Monitoring and Expectations

• Regular monitoring is essential to assess response and adjust treatment as needed, according to the American College of Cardiology guidelines 12, 13
• For liraglutide 3.0 mg: If the patient has not lost at least 4% of body weight after 16 weeks, the medication should be discontinued, as recommended by the American Heart Association 12, 13

Common Pitfalls and Considerations

• Inadequate titration of GLP-1 agonists can delay maximum effectiveness, as reported by the American Gastroenterological Association 15
• Weight regain occurs after discontinuation of GLP-1 agonists, suggesting long-term use is necessary for sustained weight loss, according to the American College of Cardiology guidelines 14
• Patients with certain conditions such as pancreatitis, medullary thyroid cancer, or MEN2 should avoid GLP-1 agonists, as recommended by the American College of Cardiology guidelines 12, 13

GLP-1 Receptor Agonists for Weight Loss

Mechanisms of Action

• GLP-1 works in concert with other satiety hormones like PYY and CCK to control food intake, activating GLP-1 receptors in the hypothalamus and brainstem to suppress appetite and increase satiety 16
• The combined effect of GLP-1 receptor agonists is early satiation and reduced food consumption through delayed gastric emptying and central nervous system effects 16

Efficacy for Weight Loss

• Tirzepatide, a dual GIP/GLP-1 receptor agonist, shows weight loss of 15-20.9% at higher doses 17

Clinical Considerations

• Recent heart failure decompensation may be a contraindication for some GLP-1 receptor agonists, according to the American Heart Association, as reported in Circulation 18

Ghrelin and GLP-1 in Weight and Hunger Control

Introduction to Ghrelin and GLP-1

• Ghrelin is the only known circulating orexigenic hormone that stimulates appetite and increases food intake, while GLP-1 is an incretin hormone that suppresses appetite, delays gastric emptying, and promotes satiety—making them key opposing regulators of hunger and body weight 19

Role of Ghrelin in Appetite Regulation

• Ghrelin is secreted primarily from the gastrointestinal tract (stomach) and is the only enteroendocrine hormone that increases appetite 19
• Plasma ghrelin concentrations are inversely related to BMI—reduced in obesity and insulin resistance 19
• There is an inverse relationship between ghrelin levels and body weight, with lower levels seen in obese populations 19

Role of GLP-1 in Appetite Regulation

• GLP-1 regulates body weight by diminishing appetite and delaying gastric emptying in concert with other satiety hormones like PYY and CCK 19

Clinical Implications for Weight Management

• In obesity and insulin resistance states, the incretin effect is decreased due to increased degradation of GLP-1 by DPP-4 enzyme 19

Dysregulation in Disease States

• Ghrelin levels are reduced in both adults and children with Type 1 Diabetes 19
• Defective communication circuits between gut and brain are implicated in obesity pathogenesis 19
• The incretin effect is diminished in the proinflammatory, insulin-resistant state common in obesity 19

Weight Management with GLP-1 Receptor Agonists

Clinical Guideline Recommendations

• The American Gastroenterological Association conditionally recommends using liraglutide 3.0 mg with lifestyle interventions in adults with obesity or overweight with weight-related complications, specifically in patients who have had inadequate response to lifestyle interventions alone 20
• The baseline characteristics from major clinical trials demonstrate that GLP-1 receptor agonists were studied in populations with mean baseline BMI of 30-41 kg/m² and mean weight between 100-105 kg, as reported by the American Gastroenterological Association 20